symbol AZN
会社名 AstraZeneca Plc (アストラゼネカ)
業種 医薬品   医療関連(Health Care)
概要 アストラゼネカ(AstraZeneca PLC)はグローバルな生物医薬会社である。同社は心臓血管、胃腸、感染症、神経科学、腫瘍学及び呼吸・炎症の6つ健康分野向けに処方薬の発見・開発及び商業化を行う。同社は抗生剤などの病気治療薬、酸関連疾患治療用の「Merrem/Meronem」及び「Losec/Prilosec」を含む各種薬剤を提供する。同社商品には「Crestor」、「Atacand」、「Seloken/Toprol-XL」、「Plendil」、「Onglyza」、「Zestril」、「Symbicort」及び「Zoladex」等がある。同社は世界中で複数の研究開発(R&D)施設、生産販売施設を保有・運営する。同社は中国メキシコブラジル及びロシア等100以上の国で事業を展開している。平成23年8月31日、同社はDENTSPLY International IncへのAstra Tech事業の売却を完了した。  アストラゼネカはイギリスの大手製薬企業。循環器、消化器、感染症、神経科学、腫瘍、呼吸器関連の医療用医薬品を提供。中国ブラジル、インド、ロシアなどの新興諸国を含む100カ国超で事業を展開。主要製品は乳がん治療薬、高コレステロ―ル症治療薬、抗精神病薬、喘息治療薬、心不全治療薬、前立腺がん治療薬、高血圧・狭心症治療薬など。本社はロンドン。  AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
本社所在地 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA GBR
代表者氏名 Pascal Soriot
代表者役職名 Executive Director and Chief Executive Officer
電話番号 +44 20-7304-5000
設立年月日 33756
市場名 NYSE(ニューヨーク証券取引所)
従業員数 64400人
url www.astrazeneca.com
EBITDA (百万ドル) 7777.00000
時価総額 (百万ドル) 105410.40000
売上高 (百万ドル) 22090.00000
企業価値(EV) (百万ドル) 118843.40000
当期純利益 (百万ドル) 2155.00000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 AstraZeneca plc (ADR) revenues decreased 2% to $22.09B. Net income before extraordinary items decreased 10% to $2.16B. Revenues reflect United Kingdom segment decrease of 26% to $2.39B Sweden segment decrease of 43% to $477M Japan segment decrease of 10% to $1.95B. Net income also reflects The Americas segment loss totaling $757M vs. income of $1.24B Other Asia.



   Boom Or Bust: What Does The Future Hold For AstraZeneca PLC (NASDAQ: AZN) Stock?  2023/02/02 20:00:00 Marketing Sentinel
AstraZeneca PLC (NASDAQ:AZN)’s traded shares stood at 2.75 million during the latest session, with the company’s beta value hitting 0.54. At the last check today, the stock’s price was $62.67, to imply a decrease of -1.41% or -$0.89 in intraday trading. The AZN share’s 52-week high remains $72.12, putting it -15.08% down since that peak … Boom Or Bust: What Does The Future Hold For AstraZeneca PLC (NASDAQ: AZN) Stock? Read More »
   Amgen, AstraZeneca''s asthma therapy Tezspire''s self-administration option gets FDA approval  2023/02/02 14:42:40 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) approved a self-administration option of Amgen (AMGN) and AstraZeneca''s (AZN) asthma therapy Tezspire.The approval is for…
   AstraZeneca, Amgen''s Tezspire Pre-filled Pen Receives FDA Approval In US For Asthma  2023/02/02 14:36:00 Finanz Nachrichten
THOUSAND OAKS (dpa-AFX) - AstraZeneca Plc (AZN) and Amgen Inc (AMGN)''s Tezspire got FDA approval in the US, based on the pathfinder clinical trial program. The approval is for self-administration …
   TEZSPIRE approved for self-administration in the US with a new pre-filled pen  2023/02/02 14:00:00 Wallstreet:Online
AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1 The approval by the US Food and Drug Administration
Now Offers Patients the Choice of Administration at Home or in a Doctor''s Office THOUSAND OAKS, Calif. , Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE ® (tezepelumab-ekko) for self-administration
   AstraZeneca PLC (NASDAQ:AZN), Stock Jumps 12.36% Far This Year; What Analysts Say Next?  2022/06/09 20:00:00 Marketing Sentinel
In recent trading session, AstraZeneca PLC (NASDAQ:AZN) saw 1.93 million shares changing hands at last check today with its beta currently measuring 0.47. Company’s recent per share price level of $63.57 trading at -$1.15 or -1.78% at last check today assigns it a market valuation of $198.94B. That most recent trading price of AZN’s stock … AstraZeneca PLC (NASDAQ:AZN), Stock Jumps 12.36% Far This Year; What Analysts Say Next? Read More »
   FDA Pushes To Authorize Novavax’s Covid-19 Vaccine Despite Serious Cardiovascular Safety Issues - Geller Report  2022/06/09 19:00:32 Geller Report
Despite overwhelming evidence of the harm the Covid vaccines do and the FDA''s admission that the vaccine carried the possible risk of causing heart inflammation, particularly in young males, similar to the Pfizer, Moderna, and AstraZeneca mRNA vaccines, they are pushing to authorize this poison.
   5 Cathie Wood Stocks to Buy in June  2022/06/09 15:00:28 InvestorPlace
Many of these Cathie Wood stocks have faced significant challenges in the first half of 2022. Wood’s innovation-focused exchange-traded funds (ETFs) were all the rage on Wall Street until the recent market downturn. As Bloomberg recently reported, “Wood and her firm ARK Investment Management have been among the highest-profile victims of a stock selloff that has swept Wall Street as inflation takes off and the Federal Reserve raises borrowing costs.” Investors have been keeping away from riskier technology stocks in favor of established industries that deliver steady profits. As a result, Wood’s flagship ARK Innovation ETF (NYSEARCA: ARKK ) has fallen 50% year-to-date (YTD), whereas the S&P 500 and the NASDAQ 100 indices have only declined 11.9% and 17.4%, respectively. The recent rout in technology stocks is undeniably significant. But if history is any guide, these declines will also be temporary. Innovation will continue to be a primary driving force of the modern economy. Accordingly, our readers might want to capitalize on the current selloff to invest in tech innovators at discount prices. 7 Top-Rated Large-Cap Stocks to Buy and Hold With that information, here are the five best Cathie Wood Stocks to buy in June: Ticker Company Price EXAS Exact Sciences Corporation $47.71 IONS Ionis Pharmaceuticals, Inc. $34.74 KTOS Kratos Defense & Security Solutions, Inc. $14.69 TRMB Trimble Inc. $66.57 PATH UiPath Inc. $21.12 Cathie Wood Stocks to Buy: Exact Sciences (EXAS) Source: Tada Images / Shutterstock 52-week range: $45.25 – $133.99 Biotech group Exact Sciences (NASDAQ: EXAS ) focuses on the early detection and treatment guidance for cancer.
   AstraZeneca claims its Evusheld jab protects against severe Covid-19 or death  2022/06/08 18:29:20 Livemint
The phase-three trial was carried out mostly on participants at high risk of progression to severe Covid-19, AstraZeneca added in a statement and its Evusheld jab provided protection against severe Covid-19 or death
   Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight  2022/06/08 17:00:00 Benzinga
New York, USA, June 08, 2022 (GLOBE NEWSWIRE) -- Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight As per DelveInsight, recent advances in Cervical Cancer have provided new options for treating patients with advanced forms of the disease, fulfilling a significant unmet medical need. Advanced Cervical Cancer Pipeline involves 75+ key companies continuously working towards developing 75+ Advanced Cervical Cancer treatment therapies. DelveInsight''s '' Advanced Cervical Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Advanced Cervical Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Advanced Cervical Cancer pipeline domain. Key Takeaways from the Advanced Cervical Cancer Pipeline Report DelveInsight''s Advanced Cervical Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
   CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial  2022/06/04 14:00:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit versus chlorambucil plus obinutuzumab and a safety and tolerability profile consistent with the known profile for CALQUENCE at a median follow up of approximately five years in combination and as a monotherapy in chronic lymphocytic leukemia (CLL).1 Results also showed longer overall
   AstraZeneca PLC (NASDAQ: AZN)’s Stock Is Up 19.06% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022  2022/06/03 18:00:00 Marketing Sentinel
During the recent session, AstraZeneca PLC (NASDAQ:AZN)’s traded shares were 1.84 million, with the beta value of the company hitting 0.47. At the last check today, the stock’s price was $66.00, reflecting an intraday loss of -1.45% or -$0.97. The 52-week high for the AZN share is $71.70, that puts it down -8.64 from that … AstraZeneca PLC (NASDAQ: AZN)’s Stock Is Up 19.06% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »
   Innate Pharma to get $5M from AstraZeneca as IPH5201 heads to phase 2 study in lung cancer  2022/06/03 08:59:45 Seeking Alpha
France''s Innate Pharma (IPHA) said it will receive a $5M milestone payment from AstraZeneca (AZN) as its monoclonal antibody IPH5201 will advance into a phase 2 trial in lung…
   The Global Dementia Drugs Market is Expected to Register Immense Growth at a CAGR of 8.42% by 2027 | DelveInsight  2022/06/02 17:00:00 Benzinga
New York, USA, June 02, 2022 (GLOBE NEWSWIRE) -- The Global Dementia Drugs Market is Expected to Register Immense Growth at a CAGR of 8.42% by 2027 | DelveInsight The dementia drugs market is expected to expand due to the rising prevalence of dementia and neurological disorders, such as vascular dementia, along with the rise in healthcare expenditure by the government for promoting research and development activities and partnerships between the key players to facilitate drug development. In addition, factors such as the increasing approval of various drugs for dementia and the rising geriatric population will play a crucial role in establishing an upward growth trend in the dementia drugs market during the forecast period from 2022 to 2027. According to the latest report published by DelveInsight, " Dementia Drugs Market Insight ," the global Dementia Drugs market is expected to witness immense growth owing to an increase in the prevalence of dementia globally. Additionally, the rising focus of the pharmaceutical companies and research institutes on developing novel drugs that can help cure dementia is another critical factor driving the growth of the Dementia Drugs market across the globe.
   GRAIL collaborates with AstraZeneca to make companion diagnostic tests for early-stage cancer  2022/06/02 13:59:02 Seeking Alpha
Illumina (ILMN) unit GRAIL on Thursday announced a collaboration with AstraZeneca (AZN) to make and sell companion diagnostic assays for use with AZN''s therapies.GRAIL, which focuses…

 関連キーワード  (医薬品 米国株 アストラゼネカ AZN )

 twitter  (公式ツイッターやCEOツイッターなど)